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Introduction {#sec005}
============

Genomic instability and in particular its most common form chromosomal instability (i.e. structural or numerical chromosome aberrations) is thought to be an early event and driving force in tumorigenesis \[[@pone.0197522.ref001],[@pone.0197522.ref002]\]. Telomeres play a key role in the maintenance of chromosome integrity and stability. Telomere dysfunction has emerged as having a causative role in carcinogenesis by promoting genetic instability \[[@pone.0197522.ref003]\]. An essential mechanism for chromosome integrity is represented by the coverage of their end provided by telomeres. In fact, in their absence, with each cell division genetic materials would be lost \[[@pone.0197522.ref004]\].

Telomeres are functional complexes formed by repetitive sequences of DNA and proteins (shelterin) but their exact function and regulation have only recently begun to be understood \[[@pone.0197522.ref005]--[@pone.0197522.ref007]\]. Telomere length (TL) maintenance is a complex process controlled by a large number of different telomere binding proteins, some of which commonly involved in DNA repair, such as BRCA1 and BRCA2 \[[@pone.0197522.ref008]--[@pone.0197522.ref011]\]. TL in proliferating tissues progressively shortens with each division of somatic cells and TL in peripheral blood leucocytes (PBL) is considered a marker of biological age \[[@pone.0197522.ref012]\]. TL is strongly correlated across tissues \[[@pone.0197522.ref013]\]. Telomeres shorten at equivalent rates in somatic tissues of adults and PBL-TL is considered an useful surrogate for the other tissues.

Correlations between shortened telomeres and aging related diseases in humans such as cardiovascular diseases \[[@pone.0197522.ref014], [@pone.0197522.ref015]\], cognitive decline \[[@pone.0197522.ref016], [@pone.0197522.ref017]\], liver cirrhosis \[[@pone.0197522.ref018]\], premature aging syndromes \[[@pone.0197522.ref019]\] and also cancer have been reported.

The association of cancer risk with mean PBL-TL has been evaluated in a large number of epidemiological retrospective \[[@pone.0197522.ref020]--[@pone.0197522.ref027]\] and prospective \[[@pone.0197522.ref027]--[@pone.0197522.ref032]\] studies on different types of cancers, but the results are still inconclusive. In 2011 two meta-analyses \[[@pone.0197522.ref033], [@pone.0197522.ref034]\] provided suggestive evidence for an association between short TL and overall cancer risk. However the evidence that the odd ratios for retrospective studies were much higher than for the prospective studies suggested the presence of reverse causation bias and possible contribution of cancer therapy prior to sample collection. A recently published prospective study on almost 50,000 subjects followed for 20 years didn't find any association between telomere length and cancer risk, while it showed a reduced survival after cancer associated with a short telomere length \[[@pone.0197522.ref035]\]. A recent meta-analysis pooling 62 population studies observed a non- significant association between TL shortening and overall cancer risk, and for some cancers, including gastrointestinal tumors and head and neck cancers, a significant association of short telomeres with an increased risk was observed, suggesting that telomeres may play a diverse role in different cancers \[[@pone.0197522.ref036]\].

A recent Mendelian randomization study, using germ line genetic variants as variables for telomere length, confirms that longer telomeres reduce risk for some non-neoplastic diseases, but increase risk for some cancers with a large variability across cancer types and tissues \[[@pone.0197522.ref037]\]

Breast cancer (BC) is the most common cancer and the leading cause of death from cancer in women worldwide. While most BC are sporadic in nature, approximately 5--10% are attributed to genetics, arising from autosomal dominant mutations in specific cancer genes, the strongest of which are the two breast cancer susceptibility genes BRCA1 and BRCA2 (collectively named "BRCA"). Women who carry a BRCA mutation have up to an 80% lifetime risk of developing breast cancer \[[@pone.0197522.ref038]\]. BRCA1 and BRCA2 proteins, which are involved in repair of DNA double strand breaks, are localized at telomeres and may regulate TL and stability \[[@pone.0197522.ref009], [@pone.0197522.ref010]\]. In addition, BRCA2 was recently described to be implicated in telomere replication \[[@pone.0197522.ref039]\]. Several retrospective \[[@pone.0197522.ref040]--[@pone.0197522.ref044]\] and prospective \[[@pone.0197522.ref027], [@pone.0197522.ref044]--[@pone.0197522.ref047]\] case-control studies examined PBL-TL in relation to breast cancer risk but only few of them\[[@pone.0197522.ref048]--[@pone.0197522.ref051]\] assessed this relationship in women screened for BRCA mutations. Interpretation of the findings of these studies was hampered by the inconsistency of their results. The largest of these studies (BRCA1 (n = 1,628) and BRCA2 (n = 1,506) mutation carriers) of Pooley et al. \[[@pone.0197522.ref050]\] found that mutation carriers (regardless of whether cancer-affected or unaffected) have longer telomeres than individuals from the same families without mutations.

Based on this background, the aims of the present study were to provide evidence on the association between family history of BC or presence of a BRCA mutation and PBL-TL in the hypothesis that telomere length is a modifier of cancer risk.

To these aims we measured PBL-TL in cases and controls subjects characterized for family history of BC and for the presence of BRCA mutations.

Material and methods {#sec006}
====================

Study subjects {#sec007}
--------------

The subjects considered in this study were a subset from a larger population enrolled to evaluate the association between the presence of a pathogenic mutation in either or both the BRCA genes and increased MN frequencies \[[@pone.0197522.ref052]\]. The subjects were recruited in IRCCS AUO San Martino- IST- Istituto Nazionale Ricerca sul Cancro, Genova, Italy among: a) patients and their relatives referring for a genetic consultation to the Hereditary Cancer Unit; b) women attending the Radiology Unit for mammography and c) Breast cancer (BC) cases attending the Oncology Department for follow up. The entire study population includes 381 women recruited in seven years (January 2006-May 2012) with 142 cases and 239 controls. All women aged 18--80 years, with and without BC, consenting to provide a blood sample and information on their BC family history, were considered eligible for this study. Women with other cancers or with known or suspected hereditary cancer syndromes other than Hereditary Breast Ovarian Cancer were excluded. BC patients were enrolled only if they had not received chemo- or radio-therapy within 12 months before blood sampling.

The obvious bias deriving from the setting where cases and controls were selected affects the relative frequency of women with a positive family history of BC and/or a BRCA mutation, but does not affect the endpoint of our study, the PBL-TL measurement in different groups of women.

All women in the study were informed on the aims and methods of the study and gave a written consent to the use for study purposes of the clinical and family history information and to provide a blood sample which was drawn after provision of the written consent.

Detailed cancer family history information was collected by means of a personal interview with pedigree reconstruction up to three generations on both sides of the family. In all analyses, only women with BC in a 1^st^ or 2^nd^ degree relative were considered to have a positive family history.

During the study period, BRCA genetic testing was proposed to women according to protocols currently in use at the Hereditary Cancer Unit, and no test was proposed as a consequence of participation to the study. Accordingly, the results of BRCA tests were abstracted from clinical records. BRCA variant classification followed international rules \[[@pone.0197522.ref053]\] and variants were distinguished in three classes:---pathogenic;---uncertain significance (VUS);---not pathogenic or of no clinical significance.

Ethics statement {#sec008}
----------------

All research was carried out in compliance with the Helsinki Declaration.The protocol of the study and the consent procedure were approved by the local Ethical Committee of the National Cancer Research Institute of Genoa (N. ECE08.001, 07/04/08). From all participants, informed written consent to the study was obtained and recorded.

PBL-TL measurement by quantitative PCR {#sec009}
--------------------------------------

DNA was extracted from peripheral blood sample using the QIAmp DNA Mini Blood extraction Kit (Qiagen, Hiden Germany). DNA to evaluate TL was available for 142 cases and 239 controls. TL was measured in PBL DNA using the real-time quantitative PCR method developed by Cawthon \[[@pone.0197522.ref054]\] and described previously \[[@pone.0197522.ref055]\]. This method measures the relative telomere length in genomic DNA by determining the ratio of telomere repeat copy number (T) to single copy gene (S) copy number (T:S ratio) in experimental samples relative to the T/S ratio of a reference pooled sample \[[@pone.0197522.ref055]\]. The single-copy gene used in this study was human β-globin (*hbg*). A "seven-point" standard curve was generated from a serially diluted DNA pool (obtained from 50 DNA samples randomly selected from the case and control samples tested in the present study), ranging from 20 to 0.31 ng in each plate, so that relative quantities of T and S (in nanograms) could be determined from it. All samples and standards were run in triplicate and the average of the 3 *T/S* ratio measurements was used in the statistical analyses. The PCR runs were conducted in triplicate on a SteponePlus Real Time PCR System (Applied Biosystems). After PCR amplification, the specificity of the product was confirmed by dissociation curve analysis. To test the reproducibility of telomere length measurements, we amplified telomere (T) and *hbg* (S) in 15 samples that were replicated 3 times on each of 3 different days. The within-sample CV for the average T/S ratio over the 3 consecutive days was 8.5%, which was similar to the CV reported for the original protocol \[[@pone.0197522.ref054]\].

Statistics {#sec010}
----------

PBL-TL in the various subgroups were summarized as means and standard deviations, and compared by standard analysis of variance. In order to remove the confounding effect of differences in age between breast cancer cases and controls, and between subjects with and without BRCA mutations, and to assess the presence of interactions between these two variables, a multivariable Generalised Linear Model was fitted to the data with PBL-TL as the dependent variable, case/control status and presence of a BRCA/VUS mutation as factors, and age in 4 strata as a covariate. The coefficients estimated by the model should be interpreted as an adjusted difference, that is, as the weighted average difference in PBL-TL between subjects with and without each factor, estimated across strata of the other factors included in the model, with size of each stratum as weight. All p values are 2-sided. IBM SPSS, version 20 was used for all calculations.

Results {#sec011}
=======

Characteristics of the study subjects {#sec012}
-------------------------------------

The details of the study population are described in [Table 1](#pone.0197522.t001){ref-type="table"}.

10.1371/journal.pone.0197522.t001

###### Characteristics of study subjects.

![](pone.0197522.t001){#pone.0197522.t001g}

                             BC Cases N (%)   Controls N (%)   Total N. (%)
  -------------------------- ---------------- ---------------- --------------
  Total                      142 (100)        239 (100)        381 (100)
  Age                                                          
  mean (range)               56 (34--79)      48 (18--72)      51 (18--79)
  \<40                       9 (6.4)          53 (22.2)        62 (16.3)
  40--55                     49 (34.5)        126 (52.7)       175 (45.9)
  55--65                     57 (40.1)        43 (18.0)        100 (26.2)
  \>65                       27 (19.0)        17 (7.1)         44 (11.6)
  Family history                                               
  1st degree                 55 (38.8)        85 (35.6)        140 (36.7)
  2nd                        26 (18.3)        49 (20.5)        75 (19.7)
  Neg/\>2nd                  61 (42.9)        105 (43.9)       166 (43.6)
  BRCA classes                                                 
  Pathogenic variant BRCA1   12 (8.5)         8 (3.3)          20 (5.3)
  Pathogenic variant BRCA2   5 (3.5)          3 (1.2)          8 (2.1)
  VUS BRCA1                  5 (3.5)          2 (0.8)          7 (1.8)
  VUS BRCA2                  10 (7.0)         3 (1.2)          13 (3.4)
  Negative test              43 (30.3)        29 (12.1)        72 (18.9)
  NA                         67 (47.2)        194 (81.3)       261 (68.5)

NA not available

Cases were older than controls (mean age 56, range 34--79 and mean age 48, range 18--72 years, respectively) Due to the recruitment of a large number of subjects in the Hereditary Cancer Unit, the proportion of women with a positive 1^st^/2^nd^ degree family history of BC was high but not significantly different between BC cases and controls. A higher proportion of BC cases than controls was evaluated for the presence of BRCA mutations (75/142, 52,8% vs 45/239, 19.0%).

PBL-TL by case-control status {#sec013}
-----------------------------

PBL-TL in the total study population and in subgroups of subjects by case-control is reported in [Table 2](#pone.0197522.t002){ref-type="table"}.

10.1371/journal.pone.0197522.t002

###### Effect of covariates on PBL-TL by case-control status.

![](pone.0197522.t002){#pone.0197522.t002g}

                                          BC cases     Controls                    
  --------------------------------------- ------------ -------------- ------------ --------------
  Comparison between cases and controls                                            
  Crude                                   142          2.33 (0.06)    239          2.22 (0.05)
  P value                                 0.189                                    
  Adjusted for age                        142          2.16 (0.057)   239          2.36 (0.069)
  P value                                 0.025                                    
  Age                                                                              
  \<40                                    9 (6.4)      2.14 (0.32)    53 (22.2)    2.50 (0.11)
  40--55                                  49 (34.5)    2.42 (0.12)    126 (52.7)   2.21 (0.07)
  55--65                                  57 (40.1)    2.32 (0.09)    43 (18.0)    2.14 (0.11)
  \>65                                    27 (19.0)    2.23 (0.13)    17 (7.1)     1.67 (0.12)
  P value                                              0.658                       0.01
  BMI                                                                              
  \<20                                    13 (9.1)     2.49 (0.19)    32 (13.4)    2.32 (0.15)
  20--24                                  58 (40.8)    2.20 (0.10)    117 (48.9)   2.17 (0.07)
  25--29                                  25 (17.6)    2.27 (0.15)    52 (21.7)    2.15 (0.10)
  30+                                     15 (10.5)    2.48 (0.19)    11 (4.6)     2.04 (0.18)
  P value                                              0.462                       0.673
  Age at menarche                                                                  
  \<12                                    23 (16.2)    2.30 (0.18)    58 (24.3)    2.29 (0.11)
      12                                  34 (23.9)    2.28 (0.12)    62 (25.9)    2.08 (0.07)
      13+                                 56 (39.5)    2.31 (0.10)    94 (39.3)    2.18 (0.08)
  P value                                              0.980                       0.304
  Age at 1st pregnancy                                                             
  Nulliparous                             27 (19.0)    2.06 (0.15)    56 (23.4)    2.34 (0.11)
  \<25                                    32 (22.5)    2.16 (0.12)    45 (18.8)    2.09 (0.09)
  25--30                                  47 (33.1)    2.38 (0.10)    63 (26.4)    2.19 (0.10)
  \>30                                    36 (25.4)    2.63 (0.14)    75 (31.4)    2.23 (0.09)
  P value                                              0.017                       0.439
  N.of Children                                                                    
  Nulliparous                             27 (19.0)    2.06 (0.15)    56 (23.5)    2.34 (0.11)
  1                                       57 (40.1)    2.48 (0.11)    77 (32.2)    2.23 (0.09)
  2                                       45 (31.7)    2.24 (0.12)    93 (38.9)    2.19 (0.08)
  3+                                      13 (9.2)     2.55 (0.21)    13 (5.4)     1.85 (0.17)
  P value                                              0.078                       0.215
  Menopausal status                                                                
  Premenopausal                           29 (20.4)    2.43 (0.17)    147 (61.5)   2.28 (0.06)
  Postmenopausal                          113 (79.6)   2.31 (0.07)    92 (38.5)    2.13 (0.08)
  P value                                              0.460                       0.137
  Smoking Status                                                                   
  Never                                   66 (46.5)    2.25 (0.09)    113 (47.2)   2.26 (0.07)
  Current                                 21 (14.8)    2.51 (0.18)    53 (22.2)    2.20 (0.13)
  Ex smoker                               26 (18.3)    2.23 (0.15)    47 (19.7)    1.96 (0.08)
  P value                                 29 (20.4)    0.433                       0.013
  Oral Contraceptive use                                                           
  Ever                                    61 (43.0)    2.42 (0.18)    134 (56.0)   2.23 (0.06)
  Never                                   53 (37.3)    2.18 (0.10)    80 (33.5)    2.10 (0.09)
  P value                                              0.111                       0.223
  Hormone Replacement therapy                                                      
  Ever                                    15 (10.6)    2.42 (0.13)    32 (13.4)    2.03 (0.12)
  Never                                   97 (68.3)    2.28 (0.08)    180 (75.3)   2.21 (0.06)
  P value                                              0.503                       0.213
  Family history                                                                   
  1st degree                              55 (38.8)    2.27 (0.10)    85 (35.6)    2.31 (0.09)
  2nd                                     26 (18.3)    2.37 (0.16)    49 (20.5)    2.28 (0.10)
  Neg/\>2nd                               61 (42.9)    2.37 (0.10)    105 (43.9)   2.13 (0.08)
  P value                                              0.754                       0.224

PBL-TL decreases with age in controls (p = 0.01), but not in cases ([Table 2](#pone.0197522.t002){ref-type="table"} and [Fig 1](#pone.0197522.g001){ref-type="fig"}).

![Leucocyte Telomere length (PBL-TL) as a function of age in years at blood sampling in controls and breast cancer (BC) patients.\
Footnote: Control: R^2^ linear = 0.059, BC cases: R^2^ linear = 1.409 E-4.](pone.0197522.g001){#pone.0197522.g001}

The analysis of crude data didn't show any difference in PBL-TL between BC cases and controls. However, mean age-adjusted PBL-TL was lower in cases compared with controls (Mean (S.E.): 2.16(0.06) vs 2.36 (0.07) p = 0.025). PBL-TL was positively associated with age of first pregnancy (p = 0.017) in BC cases. No association between PBL-TL and BMI, age at menarche, number of children, smoking habits, oral contraceptive use and hormone replacement therapy both in BC cases and in controls was detected ([Table 2](#pone.0197522.t002){ref-type="table"})

PBL-TL by family history and BRCA status {#sec014}
----------------------------------------

No association between PBL-TL and family history was observed both in BC cases (p = 0.754) and controls (p = 0.224) ([Table 2](#pone.0197522.t002){ref-type="table"}). In [Table 3](#pone.0197522.t003){ref-type="table"} BC cases and controls were also classified according to the presence of a pathogenic mutation or a variant of uncertain significance (VUS) in the BRCA1 or BRCA2 gene. Among subjects tested negative for a mutation in either gene, mean PBL-TL was similar in cases and controls (mean (SE) = 2.58 (0.12) and 2.42 (0.15)), respectively. Among controls, no significant variation in mean PBL-TL with the BRCA mutation status was observed. The lowest mean PBL-TL value was detected in VUS BRCA2 variants (3subjects) ((Mean (S.E.): 2.19(0.19)) and the highest mean TL value was observed in VUS BRCA1 variants (2 subjects) ((Mean (S.E.): 3.36 (0.23). Among cases, significant variation in mean PBL-TL with the BRCA mutation status was observed (p = 0.006). Among BC cases the lowest mean PBL-TL value was detected in VUS BRCA2 variants (10 subjects) (Mean (S.E.): 1.78 (0.19)) no significant variation in mean PBL-TL was seen in patients tested positive for the presence of BRCA pathogenic mutations (mean (SE) = 1.94 (0.17), p = 0.397) ([Table 3](#pone.0197522.t003){ref-type="table"})

10.1371/journal.pone.0197522.t003

###### Effect of BRCA status/classes on PBL-TL in cases and controls.

![](pone.0197522.t003){#pone.0197522.t003g}

                  PBL-LTL (T/S)                                 
  --------------- --------------- ------- ------ ------- ------ ------
  Total           75              2.27    .096   45      2.44   .11
  negative test   43              2.58    .13    29      2.42   .16
  BRCA1           12              1.95    .23    8       2.23   .21
  BRCA2           5               1.92    .27    3       2.89   .30
  VUS BRCA1       5               1.79    .30    2       3.36   .23
  VUS BRCA2       10              1.78    .20    3       2.19   .19
  P                               0.006          0.284          
  BRCA            17              1.94    .17    11      2,40   0.16
  P                               0\.            0.352          

\*Standard error

Finally, BRCA/VUS mutation and cancer/control status were included in a Multivariable Generalized Linear Model as Factors, with age in 4 strata as a covariate ([Table 4](#pone.0197522.t004){ref-type="table"}). The presence of an interaction (synergism) between each pair of them on PBL-TL was evaluated. Case-control status and age were not significantly associated with PBL-TL (p = 0.113 and p = 0.356, respectively). In the multivariate model, the presence of a BRCA mutation was not associated with a decreased PBL-TL (adjusted difference = -0.339, p = 0.112). A statistically significant interaction between case-control status and a BRCA-mutation/VUS was observed (p = 0.031), but no reduction of PBL-TL was observed when the interaction between cancer status was evaluated for BRCA and VUS mutations. No interaction was seen between age and case-control status or BRCA mutation status.

10.1371/journal.pone.0197522.t004

###### Association between presence of a pathogenic mutation or variant of unknown significance (VUS) in BRCA1-2 genes and PBL-TL: Multivariate linear regression analysis.

![](pone.0197522.t004){#pone.0197522.t004g}

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                                    Adjusted Difference   S.E.     95% C.L.         F (df)      P
  ---------------------------------------------------------------------------- --------------------- -------- ---------------- ----------- -------
  Case/Control Status                                                                                                                      

      Breast Cancer vs Controls                                                0.313                 0.196    -0.075--0.702    2.549 (1)   0,113

  BRCA Mutation Status                                                                                                                     

          Mutated vs negative                                                  -0.339                0.175    -0.685--0.008    2.235 (2)   0.112

          VUS vs negative                                                      -0.273                0.219    -0.706--0.160                

  AGE                                                                                                                                      

  \<40 vs 40--55 vs 55--65 vs \>65                                             -0.078                0.084    -0.245--0.089    0.860 (1)   0.356

  Interaction between CC-status -BRCA[^a^](#t004fn001){ref-type="table-fn"}\   \                     \        \                3.568(2)\   0.031
  CC- mutational status\                                                       0.586\                0.351\   -0.109--1,280\               
  CC-VUS                                                                       1.048                 0.437    0.182--1.914                 

  Interaction AGE-BRCA[^b^](#t004fn002){ref-type="table-fn"}                   \-                    \-       \-               1.372 (2)   0.258

  Interaction CC-Status Age[^b^](#t004fn002){ref-type="table-fn"}              \-                    \-       \-               2.083 (1)   0.152
  ------------------------------------------------------------------------------------------------------------------------------------------------

^a^ See [Methods](#sec006){ref-type="sec"} and [Results](#sec011){ref-type="sec"} for the explanation of the meaning and for the interpretation of the interaction coefficient

^b^ Excluded from the final model

Discussion {#sec015}
==========

The aim of our study was to evaluate the possible association between PBL-TL and the risk factors for breast cancer, mainly focusing on familiar and genetic factors (i.e. BRCA mutations). PBL-TL was measured in a group of healthy women and breast cancer patients with and without family history and in a subgroup of women evaluated for the presence of BRCA mutations.

Shorter PBL-TL was observed in our study in BC cases with respect to controls after adjusting for age. Several retrospective \[[@pone.0197522.ref040]--[@pone.0197522.ref044]\] and prospective \[[@pone.0197522.ref027]; [@pone.0197522.ref044]--[@pone.0197522.ref047]\] case-control studies have examined PBL-TL in relation to breast cancer risk. The substantial inconsistency among the results of these studies can be accounted by a number of factors including the study design (prospective or retrospective), the use of different methods to measure TL and the potential exposure to genotoxic agents for diagnostic or therapeutic purposes. However, a strong association between shorter PBL-TL and BC risk was recently observed in a large retrospective study (2243 cases and 2181 controls) \[[@pone.0197522.ref044]\]. This suggests that telomere shortening may occur after diagnosis, possibly as a consequence of diagnostic and therapeutic procedures, and therefore, may not be of value in cancer prediction.

The main covariates that were found in previous studies to be associated with PBL-TL were analyzed in the present study. In agreement with what previously found \[[@pone.0197522.ref012]\] also in our study increasing age was significantly associated with decreasing PBL-TL of controls, while no effect of age on PBL-TL was detected in BC cases. This result is in agreement with the data reported in studies on cancer patients where the effect of age on TL is undetectable or negligible, due to the complex alterations in telomere maintenance mechanisms associated with the carcinogenic process, diagnostic and therapeutic procedures. No effect of BMI on PBL-TL was observed both in controls and in BC cases tested in our study. Contrasting results were reported on the role of BMI on PBL-TL, although TL shortening associated with increasing BMI was described in large size studies and in a recent meta-analysis \[[@pone.0197522.ref056]\].

The influence of cigarette smoking was not detected in our study in contrast with some but not all previous studies \[[@pone.0197522.ref057], [@pone.0197522.ref058]\].

No association was found between PBL-TL and the most common risk factors for breast cancer considered in our study, such as age at menarche, age of first pregnancy, number of children, use of oral contraceptive, hormone replacement therapy.

The main objective of our study was to investigate the potential association between PBL-TL and familiar factors. All the women enrolled were characterized for cancer family history, considering women with BC in a 1st or 2nd degree relative to have a positive family history. No difference in PBL-TL was observed with respect to family history both in BC cases and in controls. The large majority of studies on PBL-TL in BC didn't characterize the patients for family history. Our results are at variance with those of a study focused on hereditary BC that reported a significantly shorter PBL-TL in familial BC patients than in the control population and shorter PBL-TL associated with earlier onset of BC in successive generations of affected families \[[@pone.0197522.ref048]\].

The association between BRCA mutation status and PBL-TL was also investigated in our study in a subgroup of subjects for which data on genetic status were available. A statistically significant association between presence of a pathogenic mutation in the BRCA genes and shorter PBL-TL was observed in BC patients but not in controls. The results are difficult to interpret, because the evidence from the literature on the PBL-TL in BRCA mutation carriers is again conflicting. A number of studies reported shortened telomeres in leucocytes \[[@pone.0197522.ref048]\] or didn't find difference \[[@pone.0197522.ref049]\] in TL in BRCA mutation carriers with respect to normal populations. Recently a large study showed that BRCA mutation carriers have longer telomeres than non-mutation carriers regardless of cancer status \[[@pone.0197522.ref050]\]. Our results suggest that the difference may be due to diagnostic or therapeutic procedures in hereditary BC cases rather than to the genetic alterations.

A common bias of the studies on cancer patients, including ours, is that the enrollment is usually carried out after the diagnosis and the measurement of the PBL-TL could be affected by the diagnosis or treatment. It was been shown that chemotherapy exerts a transient telomere shortening effect \[[@pone.0197522.ref059]\] and telomere loss have been reported in BC patients following radiotherapy \[[@pone.0197522.ref060]\]. Despite our efforts to exclude patients recently treated with antiblastic drugs or radiations we can't rule out the effects of exposures associated with chromosome instability and telomere loss in cancer patients recruited in our study.

In conclusion, our study fails to provide support to the hypothesis that PBL-TL is associated with the risk of hereditary BC, or that is a marker of inherited mutations in BRCA genes, suggesting instead that some of the correlations reported in the past may be due to the confounding effect of the procedures carried out in BC patients after diagnosis.
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